Jabbour, E., Sasaki, K., Ravandi, F., Short, N. J., Garcia-Manero, G., Daver, N., . . . Kantarjian, H. (2019). Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab vs. Standard Intensive Chemotherapy (hyper-CVAD) as Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Cancer.
Dyfyniad Arddull ChicagoJabbour, Elias, et al. "Inotuzumab Ozogamicin in Combination With Low-Intensity Chemotherapy (mini-hyper-CVD) With or Without Blinatumomab Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis." Cancer 2019.
Dyfyniad MLAJabbour, Elias, et al. "Inotuzumab Ozogamicin in Combination With Low-Intensity Chemotherapy (mini-hyper-CVD) With or Without Blinatumomab Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis." Cancer 2019.